In a research report released today, H.C.
In a research report released Tuesday, Maxim analyst Jason Kolbert maintained a Buy rating on shares of OncoSec Medical Inc (NASDAQ:ONCS) with a $17.00 …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced enrollment of the first patient into the Phase II Investigator Sponsored …
Those that follow my biotech recommendations know that I look for undervalued small cap stocks with significant upside. Some may be momentum plays, …
OncoSec Medical Inc (NASDAQ:ONCS), a company developing DNA-based intratumoral cancer immunotherapies, announced today that Robert H. Pierce, MD, Chief Scientific Officer, will participate …
My investment strategy is simple. Find small-cap undervalued biotech companies with promising drugs and significant short and long term upside.
NASDAQ: CHRS– We recommended investors buy Coherus a few weeks ago under the IPO price when it was trading around $13.10.
In a research report sent to investors today, H.C.
Maxim Group analyst Jason Kolbert is out today with his second note this week on OncoSec Medical (OTC:ONCS) maintaining a Buy rating with a $3.00 …
In a research report sent to investors today, Maxim Group analyst Jason Kolbert reiterated a Buy rating on OncoSec Medical (OTC:ONCS) with a …
